VEEV · Veeva Systems Inc
Price
Snapshot
50 fields · last close| Market Cap | $50.68B |
| P/E | 50.14 |
| Float | 148.3M |
| Beta | 0.89 |
| Volatility | 22.2% |
| Exchange | NYSE |
| Sector | Health Care |
| Cap tier | Large cap |
| Macro sensitivity | Moderate |
| Clavix score | 67.5 |
| Price | 309.79 |
| Change | −0.18% |
| Prev Close | 310.36 |
| Open | 295.67 |
| Day Low | 295.67 |
| Day High | 315.02 |
| Avg Vol | 1 |
| Avg $ Vol | $409.0M |
| 52W High | 313.03 |
| 52W Low | 148.05 |
| 52W Pos | 98.0% |
| From High | −1.04% |
| From Low | +109.25% |
| Max DD 1Y | −49.37% |
| Spread | 0.10% |
| Liquidity | Normal |
| SMA 20 | +9.73% |
| SMA 50 | +16.04% |
| SMA 200 | +51.53% |
| RSI (14) | 74.0 |
| Vol 30D | 33.5% |
| Vol 90D | 45.0% |
| 1Y Range | 148–313 |
| Daily bars | 535 |
| Perf Week | +9.90% |
| Perf Month | +18.17% |
| Perf Quarter | +60.22% |
| Perf Half Y | +86.67% |
| Perf Year | +8.82% |
| Perf YTD | +41.14% |
| Prev Day | −0.18% |
| Clavix | B- |
| Debt / Eq | 0.00 |
| Curr Ratio | 4.89 |
| Int Cover | 189.7× |
| FCF Margin | 44.3% |
| Rev Growth | +16.3% |
| Profit | Profitable |
| Leverage | Low |
| Sector rank | 45 / 49 |
Clavix risk grade
regraded every trading dayVEEV grades B-, 67.5 of 100. Steadiest on Sector Resilience (73), most exposed on Price Stability (52, mixed). 1 of the 4 weighted dimensions sit above the Health Care median. Ranks 45 of 49 in Health Care by Clavix score.
How rough the ride is
| VEEV | Health Care median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 0.89 | 0.84 |
| Volatilityannualized | 22.2% | 21.1% |
| Max drawdown, past yearworst peak-to-trough fall | −49.4% | — |
| Typical daily movemedian absolute daily change | 1.27% | — |
| Days beyond ±3%of the last 252 sessions | 60 (24%) | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| VEEV | Health Care median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 0.89 | 0.84 |
| Macro sensitivityrate, dollar and credit exposure bucket | Moderate | Moderate 53% of 49 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Health Care names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| VEEV | |
|---|---|
| 1 week | +9.9% |
| 1 month | +18.2% |
| Year to date | +41.1% |
| 1 year | +8.8% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| VEEV | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30 since 22 Aug |
| Average score0 most bearish, 100 most bullish | 73 |
| Bullish · bearisharticles above 60 · below 40 | 28 · 2 |
| Directionarticles whose tone is improving vs worsening | 28 ↑ 2 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 49 Health Care names Clavix covers; the tick is the sector median.
Growth
| VEEV | |
|---|---|
| Revenue growthyear over year | +16.3% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Health Care median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Recent news
most recent scored articles · the chip is the article’s score · click to openVeeva is expanding its existing partnership with IQVIA to include a clinical operations software suite, a set of tools used to manage and run clinical trials for new drugs. The article says the move is meant to broaden Veeva's market reach through wider customer adoption and more integrated workflows.
Jim Cramer highlighted Veeva Systems on Mad Money as a software company that recovered from fears of AI disruption, noting that its pharma and biotech clinical trial platform was always difficult to disrupt. The article also notes that Eli Lilly committed to Vault CRM globally in August and Amgen followed in September, and that Veeva's fiscal Q2 (ended July 31) revenue rose 18% to $928 million.
Veeva Systems said more than 175 emerging biotech companies now use its Veeva Basics platform for drug development, and that its Data Quality System has processed and cleaned data for over 1 million subjects across more than 1,000 clinical studies. Management described the updates as progress toward more automated handling of clinical trial data for life sciences customers.
Veeva Systems is transitioning clients from Salesforce infrastructure to its own Vault CRM platform, with 14 of the world's top 20 biopharma companies signed on. Quarterly revenue of $928 million was up 18% from a year prior, and full-year guidance was raised to about $3.7 billion.
The article is a brief overview of Veeva Systems' business, describing it as a software provider for biotech and pharmaceutical companies that handles R&D, regulatory submissions, and commercial operations. No specific news, event, or development is reported. The article is insufficient to draw implications.
Nearest peers by size
Health Care| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| EW | Edwards Lifesciences Corp | A- | $50.78B | 49.39 | 0.84 | Compare |
| HUM | Humana Inc | B | $51.90B | 40.93 | 0.67 | Compare |
| BDX | Becton Dickinson and Co | A- | $52.78B | 55.76 | 0.24 | Compare |
| MDLN | Medline Inc | B | $48.08B | 69.38 | 0.95 | Compare |
| CAH | Cardinal Health Inc | A- | $58.75B | 33.97 | 0.55 | Compare |
| IDXX | IDEXX Laboratories Inc | B+ | $43.11B | 37.51 | 1.56 | Compare |
| BSX | Boston Scientific Corp | B | $63.97B | 17.32 | 0.59 | Compare |
| COR | Cencora Inc | B+ | $65.15B | 24.81 | 0.59 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. 1 month free on iPhone.